<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-028X</journal-id>
<journal-title><![CDATA[Vaccimonitor]]></journal-title>
<abbrev-journal-title><![CDATA[Vaccimonitor]]></abbrev-journal-title>
<issn>1025-028X</issn>
<publisher>
<publisher-name><![CDATA[Finlay Ediciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-028X2005000100001</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Introducción de un ELISA como ensayo alternativo en la determinación de la potencia de vacunas antitetánicas]]></article-title>
<article-title xml:lang="en"><![CDATA[Introduction of an ELISA as an alternative assay for potency testing of tetanus toxoid vaccines]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[Esther María]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romeu]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[Ubel Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[Rolando]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Perojo]]></surname>
<given-names><![CDATA[Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sosa]]></surname>
<given-names><![CDATA[Regla]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Deolinda]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Labrador]]></surname>
<given-names><![CDATA[Irma]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[Adina]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Izquierdo]]></surname>
<given-names><![CDATA[Luis]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Finlay  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba.</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2005</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2005</year>
</pub-date>
<volume>14</volume>
<numero>1</numero>
<fpage>1</fpage>
<lpage>9</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-028X2005000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-028X2005000100001&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-028X2005000100001&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Por más de medio siglo de uso, la vacunación con el toxoide tetánico ha mostrado un elevado porcentaje de eficacia en la prevención del tétanos. Este trabajo pretende introducir un ensayo inmunoenzimático en fase sólida (ELISA) como método alternativo a la prueba de seroneutralización in vivo utilizada en la evaluación de la potencia de las vacunas antitetánicas.Se desarrolló un ELISA de tipo indirecto para la cuantificación de antitoxina tetánica en suero de curiel a partir de un estándar con 29 UI/mL, previamente calibrado. Se determinó la precisión, exactitud y linealidad del ensayo. Se analizó la correlación entre el ELISA y la prueba biológica mediante la evaluación de un total de 75 muestras de sueros por ambos métodos. Por último, se estudió la respuesta individual de un grupo de animales contra 15 lotes de toxoide tetánico. El ensayo demostró ser preciso y exacto, con imprecisiones inferiores al 20% y valores de recuperación entre el 90-110%. Las desviaciones del paralelismo mostraron coeficientes de variación alrededor del 10%. El análisis por regresión lineal mostró una buena correlación entre el ELISA y el ensayo biológico (R2= 0,989). El método alternativo desarrollado probó ser una herramienta útil para la determinación de la potencia de vacunas antitetánicas a partir de la evaluación independiente de la respuesta de cada animal contra el toxoide tetánico.Los niveles de seroprotección alcanzados se encontraron entre el 83-100%.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[An indirect enzyme-linked immunosorbent assay (ELISA) was developed to quantify tetanus antitoxin activity in guinea pig sera based on a previously calibrated standard. This test is proposed as an alternative to the traditional in vivo neutralization assay used for potency evaluation of tetanus vaccines.The accuracy, precision and linearity of our ELISA were determined. Both methods were used to evaluate 75 guinea pig sera and the results were compared by linear regression analysis. The individual immunological responses against different lots of tetanus vaccine were also studied. The ELISA showed an excellent accuracy, with recovery values between 90-110%; intra, inter and total-assay imprecision ranging around 10% and parallelism deviations below 10%. A high correlation was found between our ELISA and the in vivo neutralization assay (R2= 0,989). The seroprotection levels of the tetanus vaccines tested were over 83%. All those results indicate our ELISA is an excellent alternative procedure for potency testing of tetanus toxoid vaccines.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ELISA]]></kwd>
<kwd lng="es"><![CDATA[métodos alternativos]]></kwd>
<kwd lng="es"><![CDATA[ensayos in vitro]]></kwd>
<kwd lng="es"><![CDATA[toxoide tetánico]]></kwd>
<kwd lng="en"><![CDATA[ELISA]]></kwd>
<kwd lng="en"><![CDATA[alternative methods]]></kwd>
<kwd lng="en"><![CDATA[in vitro tests]]></kwd>
<kwd lng="en"><![CDATA[tetanus toxoid]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2" face="Verdana"><strong>ARTICULOS ORIGINALES </strong></font></p>     <p align="right"></p>     <p align="right"><font size="2" face="Verdana"><strong><font size="4">Introducci&oacute;n de un ELISA como ensayo alternativo en la   determinaci&oacute;n de la potencia de vacunas antitet&aacute;nicas.</font></strong></font></p>     <p align="right"></p>     <p align="right"><strong><font size="3" face="Verdana">Introduction of an ELISA as an alternative assay for potency testing of tetanus toxoid   vaccines.</font></strong><font size="3" face="Verdana"><br /> </font></p>     <p><font size="2" face="Verdana"><strong>Juan Carlos Ram&iacute;rez, Esther Mar&iacute;a Fajardo, Beatriz Romeu, Ubel Jes&uacute;s Ram&iacute;rez, Eduardo &Aacute;lvarez,  Rolando Ochoa, Alicia Perojo, Regla Sosa, Deolinda Silva, Irma Labrador, Adina Garc&iacute;a, Pablo Gonz&aacute;lez,  Luis Izquierdo.<br />  </strong></font></p>     <p><font size="2" face="Verdana">Instituto Finlay. Centro de Investigaci&oacute;n-Producci&oacute;n de Vacunas y Sueros. Ciudad de La Habana, Cuba.  E-mail: <a href="emailto:jcramirez@finlay.edu.cu">jcramirez@finlay.edu.cu</a><br />  </font></p> <hr />     <p><font size="2" face="Verdana"><strong>RESUMEN</strong></font></p>     <p align="justify"><font size="2" face="Verdana">Por m&aacute;s de medio siglo de uso, la vacunaci&oacute;n con el toxoide tet&aacute;nico ha mostrado un elevado   porcentaje de eficacia en la prevenci&oacute;n del t&eacute;tanos. Este trabajo pretende introducir un ensayo   inmunoenzim&aacute;tico en fase s&oacute;lida (ELISA) como m&eacute;todo alternativo a la prueba de   seroneutralizaci&oacute;n in vivo utilizada en la evaluaci&oacute;n de la potencia de las vacunas antitet&aacute;nicas.Se desarroll&oacute; un ELISA de tipo indirecto para la cuantificaci&oacute;n de antitoxina tet&aacute;nica en suero de   curiel a partir de un est&aacute;ndar con 29 UI/mL, previamente calibrado. Se determin&oacute; la precisi&oacute;n,  exactitud y linealidad del ensayo. Se analiz&oacute; la correlaci&oacute;n entre el ELISA y la prueba biol&oacute;gica   mediante la evaluaci&oacute;n de un total de 75 muestras de sueros por ambos m&eacute;todos. Por &uacute;ltimo, se   estudi&oacute; la respuesta individual de un grupo de animales contra 15 lotes de toxoide tet&aacute;nico. El   ensayo demostr&oacute; ser preciso y exacto, con imprecisiones inferiores al 20% y valores de   recuperaci&oacute;n entre el 90&ndash;110%. Las desviaciones del paralelismo mostraron coeficientes de   variaci&oacute;n alrededor del 10%. El an&aacute;lisis por regresi&oacute;n lineal mostr&oacute; una buena correlaci&oacute;n entre el   ELISA y el ensayo biol&oacute;gico (R2= 0,989). El m&eacute;todo alternativo desarrollado prob&oacute; ser una   herramienta &uacute;til para la determinaci&oacute;n de la potencia de vacunas antitet&aacute;nicas a partir de la   evaluaci&oacute;n independiente de la respuesta de cada animal contra el toxoide tet&aacute;nico.Los niveles   de seroprotecci&oacute;n alcanzados se encontraron entre el 83&ndash;100%.<br />  </font></p>     <p><font size="2" face="Verdana"><strong>Palabras claves:</strong> ELISA, m&eacute;todos alternativos, ensayos in vitro, toxoide tet&aacute;nico.</font></p> <hr />     ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana"> <strong>ABSTRACT</strong></font></p>     <p align="justify"><font size="2" face="Verdana"> An indirect enzyme-linked immunosorbent assay (ELISA) was developed to quantify tetanus antitoxin   activity in guinea pig sera based on a previously calibrated standard. This test is proposed as an   alternative to the traditional in vivo neutralization assay used for potency evaluation of tetanus vaccines.The accuracy, precision and linearity of our ELISA were determined. Both methods were used to   evaluate 75 guinea pig sera and the results were compared by linear regression analysis. The individual   immunological responses against different lots of tetanus vaccine were also studied. The ELISA showed   an excellent accuracy, with recovery values between 90-110%; intra, inter and total-assay imprecision   ranging around 10% and parallelism deviations below 10%. A high correlation was found between our   ELISA and the in vivo neutralization assay (R2= 0,989). The seroprotection levels of the tetanus   vaccines tested were over 83%. All those results indicate our ELISA is an excellent alternative   procedure for potency testing of tetanus toxoid vaccines.<br /> </font></p>     <p><font size="2" face="Verdana"><strong>Keywords:</strong> ELISA, alternative methods, in vitro tests, tetanus toxoid</font></p> <hr />     <p align="justify" class="Estilo4 Estilo15"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Texto completo formato PDF </font></p>     <p align="justify" class="Estilo4 Estilo15"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>REFERENCIAS</strong></font></p>     <!-- ref --><p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.Halder M. Three Rs Potential in the development and quality control of immunobiologicals. AlTEEK. 2001; 18 suppl 1:13-46.<br />    <!-- ref -->   2. Hartung T. Three Rs Potential in the development and quality control of pharmaceuticals. AlTEEK. 2001; 18 suppl 1:1-12.<br />    <!-- ref -->   3. Winsnes R, et al. Serological assays as alternatives to the challenge test for batch release of tetanus vaccines for human use. Dev Biol Stand. 1999; 101:277-288.<br />    <!-- ref -->   4. Hong HA, et al. The use of alternatives to animal test in developing countries. Dev Biol Stand. 1999; 101:209-214.<br />    <!-- ref -->   5. Hill EH. In vitro alternatives to animal testing: breakthroughs and challenges. Animal Guardian. 1999; 14-16.<br />    <!-- ref -->   6. Milstien J. WHO activities towards the three Rs in the development and control of biological products. Dev Biol Stand. 1996; 86:31-39.<br />    <!-- ref -->   7. Halder M., et al. ECVAM&rsquo;s contribution to the implementation of the Three Rs in the production and quality control of biologicals. ATLA. 2002; 30:93-108.<br />   8. Zaffran M. Immunize every child: GAVI strategy for sustainable immunization services. GAVI Second Board Meeting. 2000; 9-44.<br />    <!-- ref -->   9. Peel MM. Measurement of tetanus antitoxin: II, toxin neutralization. J Biol Stand. 1980; 8: 191-207.<br />    <!-- ref -->   10. Peel MM. Measurement of tetanus antitoxin: I, indirect haemagglutination. J Biol Stand. 1980; 8:177-189.<br />    <!-- ref -->   11. Gupta RK, Maheshwari SC, Singh H. The titration of tetanus antitoxin: II, a comparative evaluation of the indirect haemagglutination and toxin neutralization tests. J Biol Stand. 1984; 12:137-143.<br />    <!-- ref -->   12. Maheshwari SC. Quantitation of tetanus and diphtheria antitoxins in mouse sera by indirect haemagglutination. J Commun Dis. 1998; 30(1):23-28.<br />    <!-- ref -->   13. Gentili G, Pini C, Collotti C. The use of an immunoenzymatic assay for the estimation of tetanus antitoxin in human sera: a comparison with seroneutralization and indirect haemagglutination. J Biol Stand. 1985; 13:53-59.<br />    <!-- ref -->   14. Hendriksen CFM, et al. Interlaboratory validation of in vitro serological assay systems to asses the Potency of Tetanus Toxoid in Vaccines for Veterinary Use. Biologicals. 1994; 22:257-268.<br />    <!-- ref -->   15. Gupta RK, Siber GR. Use of in Vitro Cell Assay and ELISA in the United States Potency Test of vaccines containing Adsorbed Diphtheria and Tetanus Toxoids. Dev Biol Stand. 1996; 86:207-215.<br />    <!-- ref -->   16. Ochoa R, et al. Validaci&oacute;n de un ELISA para la cuantificaci&oacute;n de antitoxina tet&aacute;nica en suero humano. Vaccimonitor. 2000; 9(4):16-21.<br />    <!-- ref -->   17. Van der Gun J, et al. Validation of the toxinbinding inhibition (ToBI) test for estimation of the potency of the tetanus toxoid component in vaccines. Dev Biol Stand. 1996; 86:199-206.<br />    <!-- ref --> 18. Habermann E, Wiegand H. A rapid and simple radio immunological procedure for measuring low concentrations of tetanus antibodies. Naunyn Schmiedebergs Arch. Pharmacol. 1973; 276:321-326.<br />    <!-- ref --> 19.Aggerbeck H, Norgaand-Pedersen B, Heron I. Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen, timeresolved fluorescence immunoassay. J Immunological Methods. 1996; 190:171-183.<br />    <!-- ref -->   20. Maple PAC, Jones CS, Andrews NJ. Time resolved fluorometric immunoassay, using europium labelled antihuman IgG, for the detection of human tetanus antitoxin in serum. J Clin Pathol. 2001; 54(10):812-815.<br />    <!-- ref -->   21. Layton GT. A micro enzyme linked immunosorbent assay (ELISA) and radioimmunosorbent technique (RIST) for the detection of immunity to clinical tetanus. Med Lab Sci. 1980; 37:323-329.<br />    <!-- ref -->   22. CPMP/SWP/728/95. Replacement of animal studies by in vitro models. European Agency for the Evaluation of Medicinal Products; 1997.<br />    <!-- ref -->   23. Charton E. Reduction and replacement of animal test in the European Pharmacopoeia: recent developments for monographs on biological substances. Pharmeuropa. 1999; 11:197-199.<br />    <!-- ref -->   24. Plikaytis BD, et al. Comparisons of standard curvefitting methods to quantitate Neisseria meningitides group A polysaccharide antibody levels by enzyme linked immunosorbent assay. J Clin Microbiol. 1991; 29:1439-1446.<br />    <!-- ref -->   25. Plikaytis BD, et al. Program ELISA user&rsquo;s manual. Atlanta: Center for Disease Control and Prevention; 1993.<br />   26. Broughton PMG, et al. Guidelines for a user laboratory to evaluate and select a kit for its own use. Part 1: Quantitative test. European Committee for Clinical Laboratory Standards; 1986.<br />    <!-- ref -->   27. Ochoa R. et al. Principios y procedimientos para la validaci&oacute;n de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad de vacunas. Vaccimonitor. 1999; 8(10):9-13.<br />    <!-- ref -->   28. WHO. Biologicals Substances. International Standards &amp; Reference Reagents; 1991.<br />    <!-- ref -->   29. FDA. Minimum requirements: Tetanus toxoid. Public Health Service; 1953.<br />    <!-- ref -->   30. Wang AS. Detection of antibodies to tetanus toxoid: comparison of the direct haemagglutination method with a radioimmunoassay. J Clin Pathol. 1982; 35: 1138-1141.<br />    <!-- ref --> 31.Melville-Smith ME, et al. A comparison of enzymelinked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983; 11:137-144</font>.    <p align="left">&nbsp;</p>     <p align="right">&nbsp;</p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Three Rs Potential in the development and quality control of immunobiologicals]]></article-title>
<source><![CDATA[AlTEEK]]></source>
<year>2001</year>
<volume>18</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>13-46</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Three Rs Potential in the development and quality control of pharmaceuticals]]></article-title>
<source><![CDATA[AlTEEK]]></source>
<year>2001</year>
<volume>18</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winsnes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Serological assays as alternatives to the challenge test for batch release of tetanus vaccines for human use]]></article-title>
<source><![CDATA[Dev Biol Stand]]></source>
<year>1999</year>
<volume>101</volume>
<page-range>277-288</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The use of alternatives to animal test in developing countries]]></article-title>
<source><![CDATA[Dev Biol Stand]]></source>
<year>1999</year>
<volume>101</volume>
<page-range>209-214</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[In vitro alternatives to animal testing: breakthroughs and challenges]]></article-title>
<source><![CDATA[Animal Guardian]]></source>
<year>1999</year>
<page-range>14-16</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milstien]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[WHO activities towards the three Rs in the development and control of biological products]]></article-title>
<source><![CDATA[Dev Biol Stand]]></source>
<year>1996</year>
<volume>86</volume>
<page-range>31-39</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[ECVAM&#8217;s contribution to the implementation of the Three Rs in the production and quality control of biologicals]]></article-title>
<source><![CDATA[ATLA]]></source>
<year>2002</year>
<volume>30</volume>
<page-range>93-108</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zaffran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Immunize every child: GAVI strategy for sustainable immunization services]]></article-title>
<source><![CDATA[GAVI Second Board Meeting]]></source>
<year>2000</year>
<page-range>9-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peel]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measurement of tetanus antitoxin: II, toxin neutralization]]></article-title>
<source><![CDATA[J Biol Stand]]></source>
<year>1980</year>
<volume>8</volume>
<page-range>191-207</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peel]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Measurement of tetanus antitoxin: I, indirect haemagglutination]]></article-title>
<source><![CDATA[J Biol Stand]]></source>
<year>1980</year>
<volume>8</volume>
<page-range>177-189</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Maheshwari]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The titration of tetanus antitoxin: II, a comparative evaluation of the indirect haemagglutination and toxin neutralization tests]]></article-title>
<source><![CDATA[J Biol Stand]]></source>
<year>1984</year>
<volume>12</volume>
<page-range>137-143</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maheshwari]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Quantitation of tetanus and diphtheria antitoxins in mouse sera by indirect haemagglutination]]></article-title>
<source><![CDATA[J Commun Dis]]></source>
<year>1998</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-28</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gentili]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Collotti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The use of an immunoenzymatic assay for the estimation of tetanus antitoxin in human sera: a comparison with seroneutralization and indirect haemagglutination]]></article-title>
<source><![CDATA[J Biol Stand]]></source>
<year>1985</year>
<volume>13</volume>
<page-range>53-59</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hendriksen]]></surname>
<given-names><![CDATA[CFM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Interlaboratory validation of in vitro serological assay systems to asses the Potency of Tetanus Toxoid in Vaccines for Veterinary Use]]></article-title>
<source><![CDATA[Biologicals]]></source>
<year>1994</year>
<volume>22</volume>
<page-range>257-268</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Siber]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of in Vitro Cell Assay and ELISA in the United States Potency Test of vaccines containing Adsorbed Diphtheria and Tetanus Toxoids]]></article-title>
<source><![CDATA[Dev Biol Stand]]></source>
<year>1996</year>
<volume>86</volume>
<page-range>207-215</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Validación de un ELISA para la cuantificación de antitoxina tetánica en suero humano]]></article-title>
<source><![CDATA[Vaccimonitor]]></source>
<year>2000</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>16-21</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van der Gun]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Validation of the toxinbinding inhibition (ToBI) test for estimation of the potency of the tetanus toxoid component in vaccines]]></article-title>
<source><![CDATA[Dev Biol Stand]]></source>
<year>1996</year>
<volume>86</volume>
<page-range>199-206</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Habermann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wiegand]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A rapid and simple radio immunological procedure for measuring low concentrations of tetanus antibodies]]></article-title>
<source><![CDATA[Naunyn Schmiedebergs Arch Pharmacol]]></source>
<year>1973</year>
<volume>276</volume>
<page-range>321-326</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aggerbeck]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Norgaand-Pedersen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Heron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Simultaneous quantitation of diphtheria and tetanus antibodies by double antigen, timeresolved fluorescence immunoassay]]></article-title>
<source><![CDATA[J Immunological Methods]]></source>
<year>1996</year>
<volume>190</volume>
<page-range>171-183</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maple]]></surname>
<given-names><![CDATA[PAC]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Andrews]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Time resolved fluorometric immunoassay, using europium labelled antihuman IgG, for the detection of human tetanus antitoxin in serum]]></article-title>
<source><![CDATA[J Clin Pathol]]></source>
<year>2001</year>
<volume>54</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>812-815</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Layton]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A micro enzyme linked immunosorbent assay (ELISA) and radioimmunosorbent technique (RIST) for the detection of immunity to clinical tetanus]]></article-title>
<source><![CDATA[Med Lab Sci]]></source>
<year>1980</year>
<volume>37</volume>
<page-range>323-329</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>European Agency for the Evaluation of Medicinal Products</collab>
<source><![CDATA[CPMP/SWP/728/95: Replacement of animal studies by in vitro models]]></source>
<year>1997</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charton]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reduction and replacement of animal test in the European Pharmacopoeia: recent developments for monographs on biological substances]]></article-title>
<source><![CDATA[Pharmeuropa]]></source>
<year>1999</year>
<volume>11</volume>
<page-range>197-199</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plikaytis]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparisons of standard curvefitting methods to quantitate Neisseria meningitides group A polysaccharide antibody levels by enzyme linked immunosorbent assay]]></article-title>
<source><![CDATA[J Clin Microbiol]]></source>
<year>1991</year>
<volume>29</volume>
<page-range>1439-1446</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plikaytis]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<source><![CDATA[Program ELISA user&#8217;s manual]]></source>
<year>1993</year>
<publisher-loc><![CDATA[Atlanta ]]></publisher-loc>
<publisher-name><![CDATA[Center for Disease Control and Prevention]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broughton]]></surname>
<given-names><![CDATA[PMG]]></given-names>
</name>
</person-group>
<source><![CDATA[Guidelines for a user laboratory to evaluate and select a kit for its own use: Part 1: Quantitative test]]></source>
<year>1986</year>
<publisher-name><![CDATA[European Committee for Clinical Laboratory Standards]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Principios y procedimientos para la validación de inmunoensayos cuantitativos empleados para evaluar la inmunogenicidad de vacunas]]></article-title>
<source><![CDATA[Vaccimonitor]]></source>
<year>1999</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Biologicals Substances: International Standards & Reference Reagents]]></source>
<year>1991</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>FDA</collab>
<source><![CDATA[Minimum requirements: Tetanus toxoid. Public Health Service]]></source>
<year>1953</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of antibodies to tetanus toxoid: comparison of the direct haemagglutination method with a radioimmunoassay]]></article-title>
<source><![CDATA[J Clin Pathol]]></source>
<year>1982</year>
<volume>35</volume>
<page-range>1138-1141</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melville-Smith]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A comparison of enzymelinked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera]]></article-title>
<source><![CDATA[J Biol Stand]]></source>
<year>1983</year>
<volume>11</volume>
<page-range>137-144</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
